Eli Lilly Moves Forward With Acquisition Of Adverum Biotechnologies

Eli Lilly's tender offer for Adverum Biotechnologies expired on Dec. 8, 2025 with 16.49 million shares—about 64% of outstanding—validly tendered; with all conditions met the companies expect to complete the merger on Dec. 9 under their existing agreement. Lilly will promptly pay $3.56 per share in cash and issue a contingent value right worth up to $8.91 tied to milestone achievements; Lilly shares were quoted at $1,002.72, down 0.52% on the NYSE.

Analysis

Eli Lilly's tender offer for Adverum Biotechnologies expired on December 8, 2025 with 16.49 million shares — approximately 64% of outstanding — validly tendered; with all conditions met Lilly will promptly pay $3.56 per share in cash and issue a contingent value right (CVR) worth up to $8.91 tied to milestone achievements, and the companies expect to complete the merger on December 9 under their existing agreement. The explicit cash-plus-CVR structure implies immediate partial cash realization for tendering shareholders and potential additional upside contingent on future clinical or commercial milestones, yielding a maximum combined consideration of $12.47 per share if all CVR conditions are satisfied. Only 64% tendered, so non-tendering holders will be absorbed through the merger mechanics at closing, leaving remaining shareholders exposed to the same cash-plus-CVR economics and to the execution risk of milestone outcomes. Lilly's stock traded at $1,002.72, down $5.15 (0.52%) on the NYSE on the report, indicating limited near-term market concern; investors should track CVR trigger criteria, milestone timelines, and any post-close integration or cash outflow disclosures that affect Lilly's balance sheet and the likelihood of achieving the $8.91 CVR payoff.

Key Decisions for Investors

• Adverum holders should assess the probability and timing of CVR milestone payments and value the $3.56 cash plus up-to-$8.91 CVR accordingly before altering positions
• Investors who did not tender should expect the merger close on Dec. 9 and evaluate whether remaining exposure to contingent milestone risk fits their risk profile
• Lilly shareholders should remain neutral-to-hold near term given the muted 0.52% share reaction but monitor announcements on CVR triggers and any disclosed cash obligations that could affect near-term liquidity
• Event-driven traders should monitor confirmation of milestone schedules and regulatory steps that determine CVR realization and avoid assuming full $8.91 payout without clear milestone delivery timelines